Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZ) Capital Expenditures: 2021-2025

Historic Capital Expenditures for Core Scientific (CORZ) over the last 5 years, with Sep 2025 value amounting to $244.5 million.

  • Core Scientific's Capital Expenditures rose 684.28% to $244.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $483.0 million, marking a year-over-year increase of 520.38%. This contributed to the annual value of $95.0 million for FY2024, which is 487.59% up from last year.
  • As of Q3 2025, Core Scientific's Capital Expenditures stood at $244.5 million, which was up 101.60% from $121.3 million recorded in Q2 2025.
  • Core Scientific's 5-year Capital Expenditures high stood at $244.5 million for Q3 2025, and its period low was -$116.1 million during Q4 2021.
  • Over the past 3 years, Core Scientific's median Capital Expenditures value was $28.8 million (recorded in 2024), while the average stood at $51.4 million.
  • In the last 5 years, Core Scientific's Capital Expenditures slumped by 99.78% in 2023 and then spiked by 3,768.55% in 2025.
  • Quarterly analysis of 5 years shows Core Scientific's Capital Expenditures stood at -$116.1 million in 2021, then surged by 220.81% to $140.2 million in 2022, then crashed by 91.70% to $11.6 million in 2023, then spiked by 146.96% to $28.8 million in 2024, then surged by 684.28% to $244.5 million in 2025.
  • Its last three reported values are $244.5 million in Q3 2025, $121.3 million for Q2 2025, and $88.4 million during Q1 2025.